1. Metabolic Enzyme/Protease
  2. FXR
  3. FXR agonist 13

FXR agonist 13 是一种选择性强、口服有效的高效 FXR 激动剂 (EC50 = 0.097 μM),且具有良好的肝微粒体代谢稳定性。FXR agonist 13 与 FXR-LBD 直接结合后表现出中等亲和力 (KD = 14.74 μM)。FXR agonist 13 对相关核受体,包括 LXRα/β、PPARα/γ/δ、PXR 和 TGR5,均表现出良好的选择性。FXR agonist 13 可用于代谢相关性脂肪性肝炎 (MASH) 的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

FXR agonist 13

FXR agonist 13 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

FXR agonist 13 is a selective, orally active, potent FXR agonist (EC50 = 0.097 μM) and has favorable hepatic microsomal metabolic stability. FXR agonist 13 exhibits moderate affinity for FXR-LBD upon direct binding (KD = 14.74 μM). FXR agonist 13 displays good selectivity against related nuclear receptors, including LXRα/β, PPARα/γ/δ, PXR, and TGR5. FXR agonist 13 can be used for the study of metabolic-associated steatohepatitis (MASH)[1].

体外研究
(In Vitro)

FXR agonist 13 (Compound E2) (24 小时) 表现出强效的 FXR 激动剂活性,在 HEK293T 细胞中 EC50 值为 0.097 μM,最大效力 (Emax) 为 92.4 %[1]
FXR agonist 13 (20 μM,24 小时) 对 HEK293T 细胞中的 LXRα/β、PPARα/γ/δ、PXR 和 TGR5 没有显著的激活作用[1]
FXR agonist 13 (0.1 μM,0-60 分钟) 的代谢主要由 CYP3A4/5 和 CYP2C8 负责[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

FXR agonist 13 (Compound E2) (3-30 mg/kg,口服,每日一次,持续 4 周) 通过抑制脂质生成和炎症通路,有效改善肥胖和 MASH 小鼠模型的肝脂肪变性、炎症和纤维化[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Obesity and MASH models were induced in male C57BL/6J mice (6 weeks old, initial weight 18-22 g) by feeding them a high-fat diet (HFD, 60% of calories from fat) for 12 weeks[1].
Dosage: 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration: P.o., once daily for 4 weeks
Result: No significant improvement in body weight, but a significant decrease in liver weight ratio, indicating a reduction in liver lesions.
Improved liver appearance; H&E staining showed reduced steatosis and hepatocellular damage.
Significantly reduced serum ALT and AST levels(10 mg/kg).
Reduced serum total cholesterol (TC) levels, but had little effect on high-density lipoprotein (HDL).
Significantly reduced hepatic triglyceride (TG) and total cholesterol (TC) levels.
Significantly reduced HYP content, downregulated lipogenesis-related genes (SREBP-1c and ACC-1), but did not affect FGF15 expression.
分子量

533.90

Formula

C26H20ClF4N3O3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
FXR agonist 13
目录号:
HY-178959
需求量: